KLK3 and cancer: Based on recent reports on the deficiencies of PSA as a diagnostic tool (Thompson et al., 2006; Simmons et al., 2011), the consensus of all recommending bodies is that the risk of routine PSA screening (e.g., unnecessary tests and/or surgeries for indolent cancers) far outweighs the benefits.